RemeGen Co., Ltd. (SHA:688331)

Market Cap	22.43B
Revenue (ttm)	1.91B
Net Income (ttm)	-1.37B
Shares Out	n/a
EPS (ttm)	-2.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,454,010
Average Volume	6,320,296
Open	48.00
Previous Close	45.46
Day's Range	47.51 - 49.79
52-Week Range	22.37 - 57.70
Beta	0.37
RSI	54.07
Earnings Date	Apr 28, 2025

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical tri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 2,999
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688331

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.